LifeArc

LifeArc is self-funded through royalty streams generated by its legacy patent portfolio, most notably the antibody humanization technology used in Keytruda. It does not solicit external limited partners or manage commingled funds. Its commercial returns are recycled into new translational research grants and equity investments.

LifeArc originated as MRC Technology, a private company established by the UK Medical Research Council in 2000 to commercialize publicly funded discoveries. It changed its name to LifeArc in 2017 and operates today as an independent medical research charity with no ongoing governance link to the MRC.

Yes. LifeArc Ventures, the charity's venture investment arm, takes direct equity in seed and Series A-stage therapeutics and health-tech companies. Additionally, LifeArc's drug discovery collaborations typically include milestone and royalty-sharing structures that give it ongoing participation in asset value.

LifeArc focuses on the translational gap between academic bench research and investable clinical assets. It funds projects through lead optimization, preclinical validation, and early clinical readiness, a stage often viewed as too early for institutional venture capital and too applied for public research grants.

LifeArc has publicly committed funding to neurodegeneration, rare respiratory diseases, infectious disease diagnostics, and global health. It launched dedicated programs for motor neuron disease and bronchiectasis in recent years, and also maintains a broader pipeline in oncology and inflammatory disease through its legacy royalty interests.